Cyclophosphamide News and Research

RSS

Cyclophosphamide is a drug that is used to treat many types of cancer and is being studied in the treatment of other types of cancer. It is also used to treat some types of kidney disease in children. Cyclophosphamide attaches to DNA in cells and may kill cancer cells. It is a type of alkylating agent. Also called CTX and Cytoxan.

Cyclophosphamide is a synthetic alkylating agent chemically related to the nitrogen mustards with antineoplastic and immunosuppressive activities. In the liver, cyclophosphamide is converted to the active metabolites aldophosphamide and phosphoramide mustard, which bind to DNA, thereby inhibiting DNA replication and initiating cell death.

Antibiotic use may affect efficacy of cancer immunotherapies

Antibiotic use is known to have a near-immediate impact on our gut microbiota and long-term use may leave us drug-resistant and vulnerable to infection.

2 Mar 2018

Stem cell transplant can effectively treat patients with rare autoimmune disease, study shows

An unusual autoimmune disease that causes skin and lung damage can be treated effectively by stem cell transplant, a new study in the New England Journal of Medicine has found.

12 Jan 2018

Stem cell transplant improves survival among scleroderma patients

Scleroderma with internal organ involvement is a debilitating and lethal autoimmune disorder with few effective treatments. But a study led by Duke Health researchers has found new cause for optimism using an aggressive stem cell transplant regimen.

5 Jan 2018

Combination of chemotherapy and targeted drug improves response in younger CLL patients

Among younger patients newly diagnosed with chronic lymphocytic leukemia (CLL), treatment with a combination of chemotherapy and a molecularly targeted drug significantly improves response over what is typically seen with chemotherapy alone, according to an investigator-initiated multi-center phase II clinical trial.

11 Dec 2017

Immunotherapy combination offers new hope for women with early stage triple negative breast cancer

A Yale Cancer Center clinical trial combining the immune checkpoint inhibitor (durvalumab/MEDI4736) with chemotherapy as preoperative treatment for early stage triple negative breast cancer disclosed a 71% pathologic complete response to the combination treatment in the initial phase I trial.

2 Jun 2017

Study finds no clear benefit of stem-cell transplant for double-hit lymphoma patients in remission

Patients with double hit lymphoma (DHL) who undergo autologous stem-cell transplantation (autoSCT) after achieving remission are not more likely to remain in remission or live longer than patients who do not undergo autoSCT, according to a new analysis from the Perelman School of Medicine and the Abramson Cancer Center of the University of Pennsylvania.

15 May 2017

Hematologist-oncologist to lead bone marrow transplantation program for treating blood-borne cancers

Hematologist-oncologist Ahmad Samer Al-Homsi MD, MBA, will lead a new bone marrow transplantation program at NYU Langone's Perlmutter Cancer Center for treating blood-borne cancers, including leukemia, lymphoma and multiple myeloma, and potentially utilize transplantation as an adjunct to immunotherapy for solid tumors.

10 Apr 2017

Timing of chemotherapy can have big effect on inflammation, study shows

The time of day that breast cancer chemotherapy drugs are given affects the amount of damaging inflammation in the body, a new study in mice suggests.

24 Jan 2017

MUSC scientists design novel antibody-based therapy to fight against cancer

Scientists at the Medical University of South Carolina (MUSC) have designed an antibody-based therapy that could target the functions of TGF-beta that cause cancer

12 Jan 2017

FDA approves expanded use of systemic therapy for treating chronic moderate-to-severe pediatric psoriasis

Amgen today announced that the U.S. Food and Drug Administration has approved the supplemental Biologics License Application for the expanded use of ENBREL (etanercept), making it the first and only systemic therapy to treat pediatric patients (ages 4-17) with chronic moderate-to-severe plaque psoriasis.

7 Nov 2016

Right dose of CAR T cells and lymphodepletion can achieve good response rates for NHL patients

In a paper published today in Science Translational Medicine, researchers from Fred Hutchinson Cancer Research Center shared data from an early-phase study of patients with advanced non-Hodgkin lymphoma (NHL) who received JCAR014, a Chimeric Antigen Receptor (CAR) T cell treatment, and chemotherapy.

9 Sep 2016

Researchers identify higher risk of early chemotherapy-related death in older patients with DLBCL

Although diffuse large B-cell lymphoma (DLBCL) is a curable disease in most patients aged 65 years or older, these patients are also at higher risk of chemotherapy-related death within the first 30 days of treatment.

9 Sep 2016

Immunotherapy drug combination shows prominent therapeutic effect against advanced and metastatic cancers in mice

A drug combination designed to enhance the immune system's ability to zero in and attack cancer cells has shown a pronounced therapeutic effect against advanced and metastatic cancers in mice, according to a Mayo Clinic study, published in the July 12 edition of the online journal Oncotarget.

12 Jul 2016

Everolimus combined with standard R-CHOP therapy shows promise in treating DLBCL patients

The targeted therapy everolimus may be safely combined with R-CHOP for new, untreated diffuse large B-cell lymphoma according to the results of a pilot study by Mayo Clinic researchers published in the Lancet Haematology.

30 Jun 2016

Scientists explain how engineered anthrax toxin proteins could help eliminate cancerous tumors

Scientists from the National Institute of Allergy and Infectious Diseases, the National Institute of Dental and Craniofacial Research, and the National Heart, Lung and Blood Institute all parts of the National Institutes of Health, describe how combining engineered anthrax toxin proteins and existing chemotherapy drugs could potentially yield a therapy to reduce or eliminate cancerous tumors.

28 Jun 2016

New stem cell treatment may halt clinical relapses, development of new brain lesions in patients MS

A new use of chemotherapy followed by autologous haematopoietic stem cell transplantation (aHSCT) has fully halted clinical relapses and development of new brain lesions in 23 of 24 patients with multiple sclerosis (MS) for a prolonged period without the need for ongoing medication, according to a new phase 2 clinical trial, published in The Lancet.

13 Jun 2016

Tandem myeloablative ASCT consolidation boosts neuroblastoma outcomes

Research presented at the American Society of Clinical Oncology annual conference suggests that consolidation therapy with tandem compared with single myeloablative autologous stem cell transplant can improve outcomes in paediatric patients with high-risk neuroblastoma.

12 Jun 2016

Immunoablation strengthens haemopoietic stem-cell transplantation effects in MS

Intensifying current transplant conditioning to remove rather than suppress immune cells ahead of autologous haematopoietic stem cell transplantation may result in long-term remission of multiple sclerosis, phase II trial findings show.

10 Jun 2016

Immunotherapy with experimental monoclonal antibody could reduce neuroblastoma tumors

Neuroblastoma tumors shrank, some dramatically, in 80 percent of newly diagnosed, young, high-risk patients enrolled in a Phase II clinical trial that included an experimental monoclonal antibody. The immunotherapy agent was produced on the St. Jude Children's Research Hospital campus where the study is still underway.

3 Jun 2016

DECT trial shows combination of epirubicin and trastuzumab improves outcomes in breast cancer patients

The study entitled "A phase II neoadjuvant sequential regimen of docetaxel followed by high-dose epirubicin in combination with cyclophosphamide administered concurrently with trastuzumab.

23 May 2016